GPRC5D CAR T-cell

Efficacy and Safety of BCMA-Targeted CAR T Therapy as Salvage Treatment in Multiple Myeloma Post-GPRC5D CAR T-Cell Failure

BCMA-targeted CAR T-cell therapy demonstrates substantial efficacy and an acceptable safety profile as a salvage option for relapsed/refractory multiple myeloma patients after failure of prior anti-GPRC5D CAR T-cell treatments.